The U.S. Food and Drug Administration (FDA) has approved a new medication called Focinvez (fosaprepitant). It is designed to help prevent nausea and vomiting that can be a side effect of chemotherapy, a common cancer treatment. This drug works by blocking a specific pathway in the body that triggers these symptoms. It is approved for use alongside other anti-nausea medicines.
This drug is for adults and children 6 months and older who are receiving certain types of chemotherapy known to cause severe nausea. It is specifically for preventing symptoms, both right after treatment and in the days that follow. The approval is particularly important for patients undergoing the strongest types of chemotherapy, where controlling delayed symptoms is a major challenge.
The approval means that doctors and hospitals now have a new intravenous (IV) option to include in their standard plans for preventing chemotherapy-related sickness. For some patients who cannot take pills or need a specific type of medicine, this provides another tool to help them get through their treatment with fewer side effects.
It is important to note that this drug has not been studied for treating nausea and vomiting that has already begun. As with any new treatment, patients should talk with their doctor to understand if this option is appropriate for their specific treatment plan and overall health.
